From: Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer
Group | No | ANXA2 | ANXA4 | ||
---|---|---|---|---|---|
Mean histoscore [95 % CI] | P value | Mean histoscore (95 % CI) | P value | ||
Normal | 46 | 133 [111–156] | 0.002 | 34 [21–46] | <0.001 |
Cancer | 336 | 94 [88–101] | 73 [65–81] | ||
Age | |||||
<50 year | 203 | 95 [87–103] | 0.731 | 79 [68–89] | 0.096 |
>50 year | 133 | 93 [83–103] | 65 [53–77] | ||
FIGO Stage | |||||
≤ IIA | 291 | 90 [83–97] | 0.002 | 74 [66–83] | 0.543 |
≥ IIB | 45 | 121 [103–138] | 67 [47–88] | ||
Cell type | |||||
SCC | 256 | 101 [93–108] | <0.001 | 51 [44–58] | <0.001 |
AD/ASC | 80 | 73 [62–84] | 145 [126–163] | ||
Tumor size | |||||
≤4 cm | 256 | 90 [82–97] | 0.010 | 76 [66–85] | 0.317 |
>4 cm | 80 | 109 [96–121] | 66 [49–83] | ||
LVSI | |||||
Negative | 202 | 88 [80–96] | 0.019 | 83 [72–93] | 0.005 |
Positive | 133 | 104 [93–114] | 60 [48–72] | ||
Depth of invasion | |||||
<50 % | 108 | 70 [60–80] | <0.001 | 70 [55–84] | 0.565 |
≥50 % | 228 | 106 [98–113] | 75 [65–85] | ||
LN metastasis | |||||
Negative | 256 | 88 [81–95] | 0.002 | 76 [66–85] | 0.250 |
Positive | 80 | 113 [100–127] | 65 [50–81] | ||
PM involvement | |||||
Negative | 305 | 92 [85–98] | 0.031 | 74 [65–82] | 0.662 |
Positive | 31 | 118 [95–141] | 68 [42–94] | ||
Resection margin | |||||
Negative | 323 | 94 [87–100] | 0.420 | 75 [66–83] | 0.032 |
Positive | 13 | 111 [66–157] | 43 [15–71] | ||
Primary Treatment | |||||
OP only | 171 | 82 [73–90] | <0.001 | 78 [66–90] | 0.354 |
OP + RT | 70 | 110 [95–125] | 71 [53–89] | ||
OP + CCRT | 90 | 107 [95–119] | 68 [54–82] | ||
Neoadjuvant | 5 | 75 [45–105] | 26 [8–59] |